trinetx built-in algorithm (TriNetX Inc)
90
Structured Review
TriNetX Inc
trinetx built-in algorithm
Trinetx Built In Algorithm, supplied by TriNetX Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trinetx+built-in+algorithm/trinetx+built+in+algorithm/pm40412616-79-15-5
Average 90 stars, based on 1 article reviews
Trinetx Built In Algorithm, supplied by TriNetX Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trinetx+built-in+algorithm/trinetx+built+in+algorithm/pm40412616-79-15-5
Average 90 stars, based on 1 article reviews
trinetx built-in algorithm - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Irritable Bowel Syndrome Is an Independent Risk Factor for Developing Opioid Use Disorder in Patients with Inflammatory Bowel Disease. Article Snippet: We used the Article Title: The Association between Hormone Replacement Therapy and Gastroparesis in Post-Menopausal Women: A Worldwide Database Analysis Article Snippet: One-to-one Article Title: SGLT2 inhibitors and cardiovascular outcomes in patients with left ventricular assist devices. Article Snippet: Introduction: Left ventricular assist devices (LVADs) provide critical support for patients with advanced heart failure (HF), but complications and suboptimal outcomes remain challenges.. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise in HF, but their role in patients with LVADs is not well established.. We aimed to evaluate the association of SGLT2 inhibitors with clinical outcomes and heart transplantation rates in patients with LVADs. Article Title: The temporal relationship between antibiotic and opioid prescription on the risk of developing an opioid use disorder: A national database study. Article Snippet: Background: Previously, we discovered that subjects co-prescribed both antibiotics and opioids on the same day in a hospital setting displayed an increased risk of developing an opioid use disorder (OUD) 12 months following hospital discharge.. The goal of this study was to examine whether prescribing antibiotics in the inpatient or emergency department setting at various time points before or after an opioid prescription impacted the risk OUD.. Methods: A propensity score matched cohort study was conducted to identify subjects (18–65 years old) with no previous history of OUD. Article Title: Adverse Pregnancy Outcomes in Patients with Polycystic Ovary Syndrome with Pre-Conceptional Hyperandrogenism: A Multi-Institutional Registry-Based Retrospective Cohort Study. Article Snippet: For propensity score matching, we utilized the Article Title: Diagnostic Implications of Irritable Bowel Syndrome Is an Independent Risk Factor for Undergoing Surgical Interventions in Patients with Inflammatory Bowel Disease Article Snippet: Propensity score matching for baseline characteristics was performed using the Article Title: A propensity score matched cohort study identifying an association of acne, but not oral antibiotic or isotretinoin use, with risk of incident inflammatory bowel disease. Article Snippet: Matthew T. Taylor, BA, David J. Margolis, MD, PhD, Shawn G Kwatra, MD John S. Barbieri 4 MD MBA 5 6 1) Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 7 2) Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 8 3) Department of Dermatology, Johns Hopkins University, Baltimore, Maryland 9 4) Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts 10 11 *Twitter handle: @DrJohnBarbieri 12 13 Corresponding author: 14 John S. Barbieri, MD MBA 15 Department of Dermatology, Brigham and Women’s Hospital 16 41 Avenue Louis Pasteur, 317A 17 Boston, MA 02115 18 Email: jbarbieri@bwh.harvard.edu 19 20 Funding sources: Dr. Barbieri is supported by the National Institute of Arthritis and 21 Musculoskeletal and Skin Diseases of the National Institutes of Health under award number 22 K23AR078930-01A1.. Dr. Kwatra is supported by the National Institute of Arthritis and 23 Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number 24 K23AR077073-01A1.. 25 26 Conflicts of Interest: Dr. Kwatra is an advisory board member/consultant for Abbvie, Aslan 27 Pharmaceuticals, Arcutis Biotherapeutics, Castle Biosciences, Celldex Therapeutics, Galderma, 28 Genzada Pharmaceuticals, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis 29 Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an 30 investigator for Galderma, Incyte, Pfizer, and Sanofi. Article Title: Re-Purposing FDA-Approved Drugs for Opioid Use Disorder. Article Snippet: To improve compatibility between cohorts, a propensity score-based matching on age and sex was used based on a |